Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.
Upper Gastrointestinal Cancer
DRUG: Nivolumab
Participant sociodemographics, Baseline|Participant Eastern Cooperative Oncology Group (ECOG) score, Baseline|Participant histology results, Baseline|Participant comorbidities, Baseline|Participant tumour location, Baseline|Date of tumour resection, Baseline|Participant primary upper gastrointestinal cancer diagnosis, Baseline
Initial nivolumab dosage prescribed to participants, Index date|Number of nivolumab treatments received, Up to 484 days|Nivolumab dosage modification, Up to 484 days|Nivolumab treatment duration, Up to 484 days|Reason for participant discharge, Up to 484 days|Participant adverse events (AEs), Up to 484 days|Management of participant adverse events (AEs), Up to 484 days
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.